Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF‐α) inhibitors

@article{Tragiannidis2017InvasiveFI,
  title={Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF‐$\alpha$) inhibitors},
  author={Athanasios Tragiannidis and Ioannis Kyriakidis and Ilse Z{\"u}ndorf and Andreas H. Groll},
  journal={Mycoses},
  year={2017},
  volume={60}
}
Macromolecular immunosuppressive monoclonal antibodies and fusion proteins directed against molecules or cells involved in inflammation and immunity represent a recent and important addition to our therapeutic armamentarium. Tumor necrosis alpha (TNFα) is a cytokine involved in systemic inflammation and clinical utilization of its antagonists has revolutionized treatment of juvenile rheumatoid and psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque… 
Serious Opportunistic Lower Respiratory Tract Infections in Pediatric Rheumatic Diseases During Treatment With Biologics
TLDR
Children with rheumatic diseases with rather asymptomatic, serious opportunistic lower respiratory tract infections (LRTIs) during immunomodulatory treatment are reported, aiming to identify a correlation between inflammatory biomarkers and the development of the opportunistic LRTI.
Infectious Complications of Biological Agents
TLDR
This chapter reviews the mechanisms of these novel therapeutic agents and their infectious complications in comparison to standard DMARDs, and also evaluates the risk of infections with novel biological agents now in use for various malignancies and hematological disorders.
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
TLDR
The current state of knowledge about infectious complications of biologic and small molecule immunomodulatory agents is reviewed to create a single resource relevant to a broad range of clinicians and researchers.
Pneumocystis jirovecii Pneumonia in Children with Hematological Malignancies: Diagnosis and Approaches to Management
TLDR
Immunofluorescence testing with monoclonal antibodies followed by fluorescent microscopy and polymerase chain reaction testing of respiratory specimens have emerged as the best diagnostic methods and measurement of (1-3)-β-D-glucan in the serum has a high negative predictive value in ruling out PJP.
Epidemiology of Invasive Fungal Disease in Children
TLDR
This review focuses on fungal disease epidemiology with a specific emphasis on the 2 most common pediatric IFDs, IC and invasive aspergillosis (IA).
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
TLDR
A significant number of OI is found in JIA patients on immunosuppressive therapy and the proposed list of Oi, created by consensus and validated in the Pharmachild cohort, could facilitate comparison among future pharmacovigilance studies.
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
TLDR
Although this new era of precision medicine shows promising outcomes of targeted therapies in children with leukemia or lymphoma, the results of this review stress the necessity for ongoing surveillance and suggest the need for antifungal prophylaxis in cases where IFDs are very common complications.
From mother to baby: antenatal exposure to monoclonal antibody biologics
TLDR
The potential risks of infections and reported hematological and immunological effects of antenatal mAbs exposure on the infant and guidance on the management of the exposed infant are described.
...
...

References

SHOWING 1-10 OF 101 REFERENCES
Endemic Fungal Infections in Inflammatory Bowel Disease Associated with Anti-TNF Antibody Therapy
TLDR
Considering that gastroenterologists have embraced the use TNF-&agr; inhibitors as a valuable armamentarium in the treatment of inflammatory bowel disease, they must be aware of therapy-related infectious complications, including appropriate diagnostic, therapeutic, and preventive strategies.
Infections Associated With Tumor Necrosis Factor-α Antagonists
Abstract: Tumor necrosis factor (TNF)-α antagonists are promising therapeutic agents for patients with severe autoimmune and rheumatologic conditions. Unfortunately, their use has been associated
Fungal infections complicating tumor necrosis factor alpha blockade therapy.
TLDR
A high index of suspicion in patients treated with TNF-alpha antagonists is recommended because the course of such infections can be serious or fulminant, and rapid access to health care should be provided.
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
TLDR
A high index of suspicion in patients treated with TNF-α antagonists is recommended because the course of such infections can be serious or fulminant, and rapid access to health care should be provided.
Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy.
TLDR
The management of patients who develop endemic fungal infection while receiving TNF alpha inhibitor therapy should include discontinuation of the TNFalpha inhibitor and early use of antifungal agents including polyenes and/or azoles according to the Infectious Diseases Society of America guidelines for treatment of these infections in immunocompromised hosts.
Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy
TLDR
The management of patients who develop endemic fungal infection while receiving TNFα inhibitor therapy should include discontinuation of the TNF α inhibitor and early use of antifungal agents including polyenes and/or azoles according to the Infectious Diseases Society of America guidelines for treatment of these infections in immunocompromised hosts.
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
TLDR
Postlicensure surveillance suggests that acute life-threatening histoplasmosis may complicate immunotherapy with TNFalpha antagonists, particularly infliximab.
Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy
TLDR
Despite similar intracellular fungal loads in the presence of both antibodies, lymphocyte proliferation in response to blood monocytes and alveolar macrophages infected with H. capsulatum was inhibited by the addition of physiologic doses of infliximab, whereas control antibody had no effect.
...
...